SAM Holdings Widens Net Loss in FY24 on Higher Finance Costs
SAM Holdings Widens Net Loss in FY24 on Higher Finance Costs
In contrast, the group's revenue rose by 3% YoY to $16.6m in FY24 driven by growth in radiation therapy and oncology services due to the introduction of its proton beam therapy.Loss per share was at $0.0480.
每股亏损为0.0480美元。
The Singapore Institute of Advanced Medicine (SAM Holdings) reported a net loss of $37.4m in FY24, a 106.6% increase from a net loss of $18.1m in FY23.
新加坡先进医学研究所（SaM Holdings）报告称，24财年净亏损3,740万美元，较23财年的1810万美元净亏损增长了106.6％。
It widened losses due to increased finance costs, high depreciation on new proton therapy equipment, and a decline in medical diagnostics revenue amidst strong market competition.
由于财务成本增加、新质子治疗设备的高折旧率以及在激烈的市场竞争中医疗诊断收入下降，它扩大了亏损。
In contrast, the group's revenue rose by 3% YoY to $16.6m in FY24 driven by growth in radiation therapy and oncology services due to the introduction of its proton beam therapy.
相比之下，该集团的收入在24财年同比增长3％，达到1660万美元，这要归因于质子束疗法的引入，放射治疗和肿瘤学服务的增长。
The company's basic and diluted loss per share increased to $0.0480 from $0.0279 in FY23.
该公司的基本和摊薄后每股亏损从23财年的0.0279美元增至0.0480美元。
